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 Current Status of Lung Cancer
Lung cancer is the leading cause of cancer deaths 
worldwide [1], being 85% of those non-small cell 
lung cancer (NSCLC). The last data published by 
Cancer Research UK reported the 1-year overall 
survival rate of 32% for lung cancer patients, 
while the 5-year survival rate is around 10%. 
Besides the development of new effective thera-
pies, lung cancer is still today a disease difficult 
to control.
The advent of targeted agents represents the 
most important innovation in the treatment of 
lung cancer over the last years. The discovery of 
epidermal growth factor receptor (EGFR)-
activating mutations in 2004 as oncogene driver 
in a subgroup of patients with NSCLC led to the 
development of a new family of biological agents, 
called EGFR-TKIs, which were able to selec-
tively bind and inhibit the EGFR molecular path-
way. About eight phase III randomized clinical 
trials compared EGFR-TKI gefitinib, erlotinib, or 
afatinib vs platinum-based chemotherapy as first- 
line treatment for EGFR-mutated NSCLC 
patients, all showing a significant survival benefit 
in favor of EGFR-TKIs. These drugs have revolu-
tionized the clinical management of about 40% 
Asian and 12% Caucasian NSCLC patients har-
boring EGFR mutations, whose survival out-
comes nearly doubled compared to standard 
chemotherapy. Later the discovery of the EML4- 
ALK fusion gene in about 3–8% of patients with 
NSCLC and the subsequent clinical development 
of crizotinib represented an amazing success 
story leading to the recent approval of this com-
pound as new standard first-line treatment in this 
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subgroup of patients [2]. Nevertheless in both 
cases, despite an initial impressive benefit, 
patients inevitably experience tumor progression, 
because the tumor can generate resistance to 
these treatments through genetic modifications 
like mutations or amplifications. To avoid this 
problem, pharmaceutical industries are develop-
ing new drugs that are able to overcome resis-
tance mechanisms. New generations of EGFR 
and ALK inhibitors have been recently investi-
gated in randomized clinical studies, showing a 
great efficacy and tolerability in patients who 
failed prior TKIs. Particularly osimertinib is the 
third-generation EGFR-TKI in most advanced 
stage of clinical development which is active 
against both EGFR-sensitizing and EGFR- 
resistant T790M mutation. The phase III AURA 
3 study has recently shown a significant survival 
benefit in favor of osimertinib over platinum che-
motherapy in NSCLC patients who progressed to 
prior EGFR-TKI and were T790M positive [3]. 
Similarly the new-generation ALK inhibitors 
alectinib and ceritinib also demonstrated a sig-
nificant superiority over platinum chemotherapy 
in ALK-rearranged patients who failed prior 
therapy with crizotinib [4]. However, there are 
already some data showing that resistance mech-
anisms can occur also for these new-generation 
drugs [5, 6]. In this scenario biomarker investiga-
tions have become one of the most interesting 
and studied fields of translational lung cancer 
research with the aim to estimate patients’ prog-
nosis, to monitor treatment response and to even-
tually predict both treatment efficacy and tumor 
recurrence [7, 8].
The genetic analysis of both EGFR mutations 
and EML4-ALK translocation is a crucial step at 
the time of diagnosis, in order to plan the optimal 
treatment strategy for each patient. Furthermore, 
the analysis of EGFR mutations has acquired a 
growing importance also in the follow-up of 
TKI-treated patients. In fact, almost in nearly 
60% of TKI-treated patients, the treatment effi-
cacy fails due to resistance mechanisms. The 
most common cause of TKI failure depends on 
the onset of secondary mutations; the exon 20 
T790M is the most characterized resistance 
mutation in EGFR [9].
Therefore EGFR mutational status should be 
monitored during treatment and mostly at relapse 
to choose the proper subsequent therapy. To date, 
the gold standard for the molecular analysis of a 
patient affected by NSCLC is the tissue biopsy.
Even if there is a big consensus about the use 
of tissue biopsy as a primary source of genetic 
information, we still have to face the situation 
when “the tissue becomes the issue”. This may 
happen when a strict “molecular follow-up” is 
mandatory to evaluate patient’s disease evolu-
tion. To solve this problem, liquid biopsy has 
raised as the “new ambrosia of researchers” as it 
could help clinicians to identify both prognostic 
and predictive biomarkers in a more accessible 
way [10].
 The Importance of Liquid Biopsy 
in NSCLC
One of the new hallmarks of cancer is the 
“genome instability and mutation” [11]. In lung 
cancer, it becomes a very relevant issue because 
of the high heterogeneity of this tumor. Lung 
cancer is characterized by different driver molec-
ular alterations, with EGFR mutations, ALK- 
EML4 translocations, and RAS mutation being 
the most common among others [12, 13]. The 
new targeted therapies against these driver muta-
tions have nearly doubled patients’ survival [14, 
15]. However, due to the genomic instability of 
cancer and its peculiar ability to adapt to the 
tumor microenvironment, cancer cells usually 
develop resistance mechanisms such as the 
EGFR-T790M mutation or the L1196M mutation 
during first-generation EGFR-TKIs and crizo-
tinib treatment, respectively [16, 17]. Recent evi-
dences showed that the tumor molecular 
alterations may not be homogeneously distrib-
uted within the same lesion and, what is most rel-
evant, the metastasis can present a completely 
different molecular profile as compared to the 
primary tumor [18, 19].
Therefore, the molecular analysis of the 
tumor and/or of the metastatic lesions is becom-
ing more and more requested at the time of 
PD. Unfortunately, tissue biopsy is a procedure 
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often limited by several features, including its 
invasiveness, the not easy access to different 
tumor sites, the high intra-tumor heterogeneity, 
and not ultimately the low patients’ compliance 
[20]. Thus, in the last decade, many new noninva-
sive approaches have been studied to overcome 
the aforementioned issues. Among these, liquid 
biopsy represents a valuable alternative for the 
detection of EGFR mutational status once it can-
not be performed on tissue samples according to 
international guidelines. Furthermore a liquid 
biopsy can be easily repeated at different time 
points allowing to follow the tumor molecular 
status during the treatment course [21]. This 
could help clinicians to predict disease progres-
sion over time, to identify new acquired molecu-
lar alterations, and to observe how all these 
characteristics correspond to patient’s status.
 Liquid Biopsy in Non-small Cell 
Lung Cancer
As we are describing in this book, there are many 
definitions of “liquid biopsy”. The definition is 
complex since different body fluids as urine, asci-
tes, saliva, cerebrospinal liquid or plasma can be 
considered as valuable sources of tumor 
components.
In this chapter, we are going to focus our 
attention on the main published studies investi-
gating circulating tumor cells (CTCs), circulating 
tumor DNA (ctDNA), and exosomes and other 
extracellular vesicles (EVs) in lung cancer. The 
last paragraph will be destined to describe the 
uncommon components of the liquid biopsy such 
as platelets.
 Circulating Tumor Cells (CTCs)
The circulating tumor cells are shed from both 
primary and metastatic tumor; thus they are rep-
resentative of the tumor from which they 
detached. It is known that lung cancer releases a 
limited number of CTCs, and therefore they were 
not so far considered a good field of study. 
Nevertheless, limitations of CTCs detection in 
lung cancer were mainly due to the limited avail-
able isolation methods. Thanks to the increase of 
knowledge about CTCs’ biological and physical 
characteristics, detection and isolation methods 
have been consequently improved. Nowadays, 
CTCs may become a promising field of study 
also in lung cancer [22].
CTCs can be used for two different aims: to 
evaluate the risk of metastasis and as a source of 
nucleic acid for molecular characterization. 
Indeed, CTCs are shed to the bloodstream and 
can play an important role in the metastatic pro-
cess. Moreover, since CTCs spread directly from 
the tumor, they might harbor the same mutational 
landscape that can be investigated through 
molecular analysis.
The studies on CTCs in lung cancer have 
shown heterogeneous results, mainly due to the 
different techniques and criteria used for the 
experiments. Tanaka et al. demonstrated that the 
number of CTCs is higher in patients with lung 
cancer than in those with benign disease, and the 
number of CTCs is significantly increased in 
patients with distant metastasis than in the pri-
mary ones. In the same study the authors demon-
strated a significant correlation between the 
number of CTCs in the bloodstream and the stage 
of the disease [23], but other studies have not 
showed the same results [24, 25]. The number of 
CTCs can be also a good marker of tumor growth 
and prognosis. Krebs et al. demonstrated that 
patients with five or more CTCs in 7.5 mL of 
total blood, after one cycle of chemotherapy, 
have a worse prognosis as compared to those 
with a lower number [26].
The molecular characterization of CTCs is 
technically challenging mainly because of the 
limited performance of isolation and detection 
methods. Moreover, the amount of extracted 
nucleic acids is always very poor, limiting the 
downstream applications. Indeed, new highly 
sensitive techniques, such as next-generation 
sequencing (NGS), are now available and offer 
the possibility to analyze the molecular alteration 
of CTCs in a relatively simple way.
The detection of EGFR-activating mutations 
in CTCs has revealed contradictory results. 
Maheswaran et al. first published in 2008 an 
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 article describing the identification of EGFR 
mutations in CTCs, providing exciting results. 
They analyzed EGFR mutations in both CTCs 
and ctDNA using a SARMS assay in patients 
already tested positive in tissue samples. 
Mutations in CTCs were detected in 19 out of 20 
patients with 95% sensitivity; they also detected 
T790M mutation in 2 out of 6 responding patients 
and in 9 out of 14 progressive patients. Moreover, 
in four patients they reported that levels of acti-
vating and resistance mutation (exon 19 deletion 
and exon 20 T790M, respectively) floated accord-
ing to disease status [27]. However, a study car-
ried by Punnoose et al. showed disparate results. 
In this paper the authors analyzed the EGFR 
expression through FISH showing very heteroge-
neous results. Indeed, they revealed CTCs with 
very strong signal (3+), others with very low (0), 
and other with intra-heterogenic results ranging 
from 3+ to 0, and this expression was not corre-
lated with the EGFR status on tissue. Moreover, 
when the DNA from CTCs was analyzed to 
detect EGFR mutations, only one out of eight 
EGFR- mutated patients was detected [28].
Besides EGFR mutations, it has been pro-
posed that ALK-EML4 translocations are detect-
able in CTCs using immunohistochemistry and 
FISH. The results reported in literature showed a 
high correlation between ALK-EML4 detection 
in tissue and in CTCs even if the cutoff value was 
different among the studies due the various tech-
niques used for CTCs isolation [29–31]. 
Moreover, a study performed by He et al. investi-
gated a new technique for CTC isolation compar-
ing the results with the FDA-approved methods, 
the CellSearch system. They demonstrated a cor-
relation between the ratio ALK-EML4 rearrange-
ment signal/CTCs and TNM stage, and similarly 
to other studies, the count of CTCs was related to 
the disease status [32]. Therefore, CTCs can be 
useful for disease follow-up as they offer the 
opportunity to evaluate both EGFR and ALK- 
EML4 alterations, as a surrogate biomarker for 
treatment response and to promptly identify 
resistance mutations responsible for treatment 
failure.
The CTC study has risen with the implemen-
tation of new isolation techniques that allow 
more reliability and the improvement of the 
molecular analysis techniques such as one-cell 
genotyping. However, a standardization of the 
techniques is needed and a big consensus on how 
the samples must be analyzed is fully required to 
make the CTC analysis truth.
 Circulating Tumor DNA (ctDNA)
The investigation of ctDNA can hypothetically 
reveal a wider genomic landscape of a tumor 
[33]. For this purpose, new sensitive technical 
approaches are available to analyze EGFR muta-
tional status from plasma-derived ctDNA. In par-
ticular, digital PCR (dPCR) and next-generation 
sequencing (NGS) platforms represent to date the 
most studied approaches for application in clini-
cal practice. Through the dPCR approach, the 
DNA sample is partitioned into thousands of 
single PCR reactions. As in the qPCR approach, 
analysis software allows to identify a positive or 
a negative signal indicating the presence or 
absence of a target sequence. Therefore, a 
mutated ctDNA can be detected in a wide back-
ground of wild-type sequences [34]. The intro-
duction of NGS technologies in clinical practice 
is the most important revolution that we have 
experienced since the discovery of polymerase 
chain reaction (PCR) and Sanger sequencing. 
Until now we have been working analyzing one 
gene at a time and one patient at a time, with 
NGS techniques this assertion has been revolu-
tionized and we can analyze multiple genes and 
multiple patients at a time with a consistent 
reduction in time and costs [35]. NGS is a high- 
throughput technique, based on massive parallel 
sequencing of thousands of DNA molecules [36]. 
There are several NGS platforms that differ 
mainly in the detection chemistry, but they all 
share some important steps: library preparation, 
library amplification, sequencing, and data analy-
sis. At the end of the analysis they all provide a 
plethora of information about the mutational 
landscape of the analyzed samples that can be 
used in clinical practice. Another great advantage 
of NGS compared to Sanger sequencing is the 
higher sensitivity, which is important when we 
C. Rolfo et al.
107
have to look for somatic and rare mutations. This 
is the case of liquid biopsy and specifically of cir-
culating tumor DNA (ctDNA) analysis. The 
information arising from ctDNA analysis will 
broad from early diagnosis to prognosis as well 
as response to drug administration and real-time 
monitoring of the disease.
 Diagnostic Role of ctDNA
To date, several studies and meta-analysis deeply 
highlighted the diagnostic value of plasma-based 
EGFR testing in NSCLC patients, showing an 
interesting accuracy of ctDNA in terms of sensi-
tivity and specificity if compared with the gold 
standard tissue genotyping [37–40]. Therefore, 
the isolation of ctDNA from plasma or serum 
would be helpful for EGFR testing in all those 
patients whose tissue is not available at diagnosis 
or tissue analysis results are inconclusive. Sacher 
et al. have recently evaluated the reliability of 
plasma analysis. This study demonstrated a high 
specificity (100%) and sensitivity (74–82%) in 
80 patients with advanced NSCLC harboring 
activating EGFR del19/L858R mutations [41] 
using droplet digital PCR (ddPCR). The same 
promising results at diagnosis have been also 
showed within the multicenter ASSESS study in 
which a similar concordance rate of 89% (sensi-
tivity 46%, specificity 97%) has been found in a 
cohort of 1162 patients with advanced NSCLC 
[42]. Furthermore, despite real-time PCR and 
ddPCR techniques are definitely the most used 
for ctDNA analysis, NGS is emerging as an 
important tool that can complement or substitute 
tissue NGS analysis. Indeed, there are several 
commercially available NGS panels specifically 
designed for ctDNA testing in lung cancer. 
Recently Villaflor et al. assessed the utility of two 
ctDNA panels in a clinical series of 68 NSCLC 
patients; the 54-gene panel includes only muta-
tions, whereas the 68-gene panel includes also 
ALK, RET, or ROS1 fusions [43]. In this paper, it 
was also investigated the concordance between 
paired tissue and blood samples whenever possi-
ble. The results reported that 80% of patients 
have detectable ctDNA, with 83% presenting at 
least one non-synonymous ctDNA alteration. As 
expected the most frequent mutations were 
reported in TP53, KRAS, and EGFR genes [43]. 
Another recent paper published on December 
2016 supports these evidences. NGS was used to 
characterize 112 plasma samples from 102 
patients with advanced NSCLC, detecting 275 
alterations in 45 genes in 84% of patients (86 of 
102). As well as reported in the paper from 
Villaflor [43], NGS was able to detect mutations 
in additional genes for which experimental thera-
pies, including clinical trials, were available. The 
concordance between tissue and plasma was 
79%, and interestingly the concordance increases 
when a shorter time interval between tissue and 
blood collection was reported [44]. Moreover, 
ctDNA sequencing enabled the detection of resis-
tance mutation in eight patients who experienced 
progressive disease during targeted therapy and 
for whom tissue analysis was not possible. 
Finally, Chen et al. prospectively evaluated the 
detection of ctDNA mutations in early-stage 
NSCLC patients (IA, IB, and IIA) by targeted 
sequencing in plasma and paired tissue samples. 
They found a considerable ctDNA concentration 
in 52 out of 58 patients, suggesting that ctDNA 
might be related to tumor cancer spread. 
Furthermore, plasma ctDNA mutations were 
identified in 35 out of 58 patient samples, with 
50% concordance between plasma and tissue 
[45]. These results suggest that ctDNA analysis 
may also be applied in early-stage disease.
 Prognostic Role of ctDNA
The prognostic role of ctDNA has been deeply 
investigated. In 2014 the group of Wang et al. 
tested the ability of dPCR to identify T790M in 
plasma ctDNA compared to a non-digital 
approach (ARMS). They showed a statistical cor-
relation between survival and allele fraction of 
circulating T790M before and after EGFR-TKI 
administration. Patients with increasing levels of 
circulating T790M during EGFR-TKI treatment 
showed better progression-free survival (PFS) 
and overall survival (OS) if compared with 
patients who do not display any significant 
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T790M variation [46]. Furthermore, in 2016 the 
same research group confirmed that patients with 
circulating T790M had a better clinical outcome 
compared to plasma T790M-negative patients 
[47]. Recently, Thompson et al. correlated sur-
vival with ctDNA levels and number of variants 
using NGS in plasma specimens of metastatic 
NSCLC patients. The high levels of ctDNA 
(>3 ng/mL), irrespective of mutational profile, 
were associated with decreased survival. 
Conversely, patients with ctDNA levels lower 
than 3 ng/mL showed a better median survival 
(24 months vs 46 months, respectively). 
Furthermore, OS seems to be strictly correlated 
with number of variants detected in plasma. 
Indeed, a number of variants greater than 3 deter-
mined an OS reduction from 62 to 46 months, 
giving thus a poorer prognosis [44]. Therefore, it 
seems that mutational load itself may be a good 
prognostic marker.
 ctDNA Value in Real-Time Monitoring 
of the Disease
The translation in clinical practice of liquid 
biopsies is strictly requested in all those cases in 
which a disease progression monitoring is 
needed (Fig. 12.1). Indeed, on November 2015 
the FDA- approved osimertinib as new treatment 
option for patients with metastatic EGFR 
T790M-positive NSCLC patients who failed 
prior EGFR-TKIs [48, 49]. Patients’ selection is 
strictly based on the identification of T790M 
mutation, and for the first time the molecular 
analysis can be performed either through tissue 
re-biopsy or in plasma samples [50, 51]. The 
noninvasive potential of ctDNA has been deeply 
studied by Oxnard in many studies specifically 
focused on the molecular biology of NSCLC. In 
2014, one of the first studies performed by its 
group highlighted the possibility to anticipate 
clinical evidence of progression through early 
molecular evidences. Indeed, the analysis of 
ctDNA through ddPCR, in serial plasma sam-
pling, allowed the detection of resistance muta-
tions (T790M) weeks and sometimes months 
prior to radiological progression [52].
Recently his group prospectively evaluated 
the sensitivity and specificity of plasma genotyp-
ing by ddPCR in 180 patients with advanced 
NSCLC, including 60 patients with acquired 
resistance to EGFR-TKI. Plasma genotyping by 
ddPCR exhibited 79% specificity and 77% sen-
sitivity in the detection of T790M mutation, 
which are lower than those observed with EGFR- 
activating mutations at baseline. In addition 
Oxnard et al. showed that outcomes of T790M- 
positive patients included in the phase I AURA 
study were similar if T790M was detected in 
plasma or tumor tissue. Conversely both RR and 
PFS of T790M-negative patients on plasma were 
significantly higher than T790M-negative on tis-
sue, and further tumor genotyping of plasma 
T790M-negative patients allowed to identify a 
subgroup of T790M-positive patients on tumor 
Serial sampling
T0 T2T1 T3
Fig. 12.1 Serial monitoring of NSCLC patients during 
treatment. Serial blood withdrawal can be obtained at dif-
ferent time points (T0, T1, T2 and T3) to detect CTCs, 
ctDNA, and exosomes; the dynamic changes of these dif-
ferent components of liquid biopsy may be useful for 
clinical management of lung cancer patients
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tissues who had better outcomes. According to 
these data, the authors suggest that plasma geno-
typing could represent the first step for the detec-
tion of T790M status at the time of PD. However, 
because of the low sensitivity (70%) of the cur-
rent available technologies which are associated 
with a 30% false negative rate, patients with 
T790M-negative on plasma should repeat tumor 
tissue biopsy to further investigate the presence 
of such molecular alteration [53]. Clinical utility 
of ctDNA testing through NGS could be also 
proven in treatment monitoring, for the evalua-
tion of tumor clone response to target treatment 
administration. Indeed, NGS analysis, as well as 
dPCR, provides also data concerning the muta-
tions allele fraction. Therefore, it is possible to 
trace allele fraction modifications over time dur-
ing a given targeted treatment and correlate these 
data with treatment response but also to predict 
relapse and disease progression [54]. In support 
of the high tumor heterogeneity, CAPP-Seq 
ctDNA studies performed by Chabon et al. on 41 
patients harboring both EGFR-activating and 
EGFR-resistant T790M mutations on tumor tis-
sue after progression to prior EGFR-TKI therapy 
revealed additional molecular alterations, includ-
ing MET alteration or HER2 increased gene 
copy number (GCN) and/or single nucleotide 
variations [55]. Since the simultaneous presence 
of such a plethora of different molecular altera-
tions has been associated with poorer outcomes 
to TKI therapies, ctDNA analysis could repre-
sent a valuable option in guiding clinicians in the 
choice of the proper treatment strategy. Notably 
it has been recently developed a novel targeted 
NGS approach for the detection of both driver 
mutations and rearrangements in ctDNA from 
advanced NSCLC patients [56]. This approach 
relies on the use of specific intronic probes that 
enable the detection of genome-level rearrange-
ments that create chimeric gene fusions in ALK, 
ROS1, and RET. The assay and analysis soft-
ware was able to identify mutation present at 
0.1% even if the diagnostic performance was 
better, reaching 100% sensitivity and specificity, 
when mutations were present at an allelic fre-
quency 0.4% or greater [56]. In addition to 
plasma, urine genotyping has also shown a high 
sensitivity in detecting T790M mutation status, 
ranging from 72% to 93%, in preliminary studies 
including few patients and is currently under 
investigation in trials including larger cohorts of 
patients [57].
 Exosomes
The interest of the scientific community on the 
role of exosomes in NSCLC is growing, and as it 
happens with CTCs, exosomes are nowadays a 
pending subject to understand. Despite the mis-
understanding of the exact exosome composition 
and function, this is becoming one of the most 
interesting fields of study in liquid biopsy. As 
aforementioned, exosomes contain a wide variety 
of material like miRNAs, proteins, and finally, 
messenger RNA that are surrounded by a lipid 
bilayer that confers stability. The exosomes differ 
from the other components of the liquid biopsy 
because they are actively released by the cells, 
earning a potential role in tumor progression.
The implementation of exosomes in clinical 
practice is several steps back as compared to 
ctDNA in NSCLC. This is mainly due to the 
lack of consensus in the best way of isolating 
exosomes from body fluids, but also to the 
high quantity of material needed to their study. 
For this reason, in this chapter we will talk about 
the principal advances in the study of exosomes 
in NSCLC that could lead to an implementation 
in the clinical practice in the following years.
The study of exosomal miRNAs is very prom-
ising, and new techniques have improved miRNA 
detection in NSCLC [58]. The new high- 
throughput technologies have allowed to identify 
differential miRNA expression between tumor- 
derived exosomes and exosomes derived from 
healthy volunteers. This has permitted the 
description of different miRNA profiles that can 
help for both tumor diagnosis and/or disease 
monitoring [59]. For example miRNA-373 and 
miRNA-512 seem to restrict both the growth and 
invasiveness of the tumor in normal conditions. 
However, in cancer patients these ncRNAs are 
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epigenetically silenced, meaning a poor progno-
sis for the patients, while if the silencing 
 disappears, the re-expression of the miRNAs 
inhibits the cell migration [60]. Regarding the 
treatment follow-up, the overexpression of miR-
208a and miR-1246 seems to promote the resis-
tance to chemotherapy in NSCLC patients. 
Similarly our group described that the overex-
pression of miR- 221- 3p and -222-3p in patients 
treated with third- generation TKI (osimertinib) is 
associated with better prognosis [58, 61, 62].
The sequencing of the exosomes transcrip-
tome is a novel field of study, and thus, the infor-
mation available are still limited. Through RNA 
sequencing it was also possible to detect EGFR 
mutations inside exosomes [63]. Accordingly we 
have recently detected the EML4-ALK translo-
cation within exosomes derived from plasma of 
NSCLC patients [64].
The high-throughput technologies for exo-
somes proteomic analysis may allow to identify 
the primary tumor and analyze its molecular pro-
file to better understand it. Regarding this, 
Yamashita et al. demonstrated that the presence 
of EGFR protein was significantly higher in the 
membrane of exosomes isolated from NSCLC 
patients compared to healthy donors [65]. Some 
other proteins have been described to be impor-
tant prognostic biomarkers; for example, 
Sandfeld-Paulsen described CD171 on the mem-
brane of the exosomes as a marker for positive 
overall survival in NSCLC [66], and also FAM3C 
have been described to be a good prognostic fac-
tor in squamous cell carcinoma patients [67]. The 
exosomes may be also helpful to the tumor diag-
nosis. Indeed, the same group has described dif-
ferent markers to discriminate the subtype of 
tumor, including also multi-marker models with 
a better discrimination curve [68].
A peculiar feature of the exosomes is their 
ability to be specifically phagocytized by cancer 
cells. This could lead to the use of exosomes as 
drug delivery components. It has been already 
demonstrated that in lung cancer mice models, 
Paclitaxel encapsulated in the exosomes could be 
an effective treatment option [69]. Moreover, two 
clinical trials using this innovative approach of 
drug delivery have been performed. The first 
approach is a Phase I trial using dendritic cell-
derived exosomes (DEX) immunotherapy; the 
second one is a Phase II trial where a vaccination 
with DEX carrying IL-15Ra and NKG2D in 
association with cyclophosphamide after plati-
num-based chemotherapy. The main objective of 
both studies was to measure the toxicity and the 
feasibility to produce autologous DEX. The 
results from both studies are eagerly awaited also 
because it has been shown that DEXs were also 
able to activate both the adaptive and the innate 
immune system [70, 71].
 How the Future of Liquid Biopsy 
Looks Like: Platelets as a Source 
of Tumor-RNA
Rearrangements of ALK, ROS1, and RET 
genes are now important as much as EGFR-
activating mutations because in this subgroup 
of patients very effective targeted treatment can 
be used. Nevertheless, it is important to point 
out that for this kind of analysis RNA is 
requested instead of DNA. This may represent a 
problem because circulating RNA undergoes 
degradation very quickly unless plasma sam-
ples are rapidly processed after withdrawal. 
Several research groups are trying to overcome 
this inconvenient. Indeed recent studies have 
shown that platelets can engulf tumor-related 
RNA preserving it from degradation, and thus 
permitting to identify primary tumor profiles 
with very high accuracy, and, in many cases, 
discriminate if the patients are metastatic or not 
[72, 73]. In 2016 Nilsson et al. have first shown 
that EML4-ALK translocation can be detected 
through RT-PCR from platelet- derived RNA 
with 65% sensitivity and 100% specificity [74] 
(Table 12.1).
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 Conclusions
In conclusion, the incorporation of ctDNA analy-
sis can definitely improve lung cancer patients’ 
management because it can provide a better 
molecular stratification even when tissue cannot 
be obtained due to ethical and safety reasons. 
Although the implementation of both exosomes 
and CTCs in clinical practice is several steps 
back, the new advances and discoveries makes 
them, together with the ctDNA, a very promising 
tool. Liquid biopsy analysis can be used in differ-
ent moments starting from diagnosis to relapse, 
earning multiple clinical meanings. In fact, at 
diagnosis, it can help in obtaining a better 
patients’ stratification with both prognostic and 
predictive value, rather than during treatment, 
and it can be a valuable and simple test to follow 
tumor response and moreover to identify resis-
tance mechanisms. Therefore it is clear that liq-
uid biopsy has already improved NSCLC 
patients’ management as it offers a noninvasive 
but valid method to detect actionable mutations.
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